Particularly, prostate-specific membrane antigen (PSMA)-targeted imaging is gaining ground due to its improved detection rate, sensitivity, and specificity compared to conventional modalities for intermediate-to-high-risk PC [134,135]. This evidence concerns the gene FOLH1 and pachyonychia congenita.